PGM2L1: A Promising Drug Target for Glucose Management and Diabetes

Target Name: PGM2L1

NCBI ID: G283209

PGM2L1

PGM2L1: A Promising Drug Target for Glucose Management and Diabetes

Introduction

Glucose-1,6-bisphosphate synthetase (PGM2L1) is a protein that plays a crucial role in glucose metabolism and is often impaired in diseases such as diabetes. PGM2L1 is a G protein-coupled receptor (GPCR), which means it interacts with specific GPCRs on target cells, allowing it to transmit signals to those cells. The primary function of PGM2L1 is to regulate glucose uptake and storage in the intestinal epithelial cells, which are the first line of defense against glucose.

PGM2L1 has been extensively studied for its potential as a drug target or biomarker for various diseases, including diabetes. In this article, we will review the current research on PGM2L1 and its potential as a drug target.

PGM2L1 Signaling

PGM2L1 is a GPCR that is expressed in most tissues and cells in the body. It is primarily localized to the endoplasmic reticulum (ER) and can be internalized by endoplasmic reticulum (ER) protein transporters (TAPs) and endoplasmic reticulum (ER) tranports ( TRPs). After internalization, PGM2L1 is phosphorylated by the enzyme src, which is a key regulator of PGM2L1 function.

src-mediated phosphorylation of PGM2L1 is a critical event in the regulation of glucose metabolism. src-mediated phosphorylation of PGM2L1 leads to the formation of a protein complex called src-PPG2L1, which is involved in the regulation of glucose uptake and storage in the intestinal epithelial cells.

In addition to src-mediated phosphorylation, PGM2L1 can also be regulated by other signaling pathways, including tyrosination and dephosphorylation. Tyrosination of PGM2L1 has been shown to enhance its transcriptional activity and promote its interaction with other proteins, including the transcription factor, Pdx1. Dephosphorylation of PGM2L1 has also been reported to play a role in its regulation, particularly in the regulation of insulin sensitivity.

PGM2L1 as a Drug Target

The potential of PGM2L1 as a drug target is based on its involvement in glucose metabolism and its regulation by src-mediated phosphorylation. Several studies have shown that inhibition of PGM2L1 function can improve glucose metabolism and reduce the risk of diseases such as diabetes.

One of the most promising strategies for targeting PGM2L1 is the use of small molecules (SMs). SMs are compounds that can inhibit src-mediated phosphorylation of PGM2L1 and enhance its function as a drug target. SMs can be further divided into two categories: inhibitors of src-mediated phosphorylation and modulators of src-mediated phosphorylation.

Inhibitors of src-mediated phosphorylation of PGM2L1 include ezetimibe, a commonly used drug for treating diabetes, and U2919, an inhibitor of src-mediated protein kinase 3 (PK3). These compounds work by inhibiting the activity of PK3, which is involved in the regulation of PGM2L1 function.

Modulators of src-mediated phosphorylation of PGM2L1 include the small molecule, N-acetyl-L-tryptophan (NALP), which is an inhibitor of src-mediated protein kinase 2 (PK2). NALP works by binding to the active site of PK2 and inhibiting its activity.

PGM2L1 as a Biomarker

In addition to its potential as a drug target, PGM2L1 is also a promising biomarker for the diagnosis and monitoring of diabetes. The impaired function of PGM2L1 has

Protein Name: Phosphoglucomutase 2 Like 1

Functions: Glucose 1,6-bisphosphate synthase using 1,3-bisphosphoglycerate as a phosphate donor and a series of 1-phosphate sugars, including glucose 1-phosphate, mannose 1-phosphate, ribose 1-phosphate and deoxyribose 1-phosphate, as acceptors (PubMed:17804405). In vitro, also exhibits very low phosphopentomutase and phosphoglucomutase activity which are most probably not physiologically relevant (PubMed:17804405)

The "PGM2L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGM2L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets